Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet
about
Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implicationsPhytosterols, Phytostanols, and Lipoprotein MetabolismSerum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patientsTreatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Influence on Adiposity and Atherogenic Lipaemia of Fatty Meals and Snacks in Daily Life.Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis.Influence of ezetimibe on selected parameters of oxidative stress in rat liver subjected to ischemia/reperfusionCholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.Cholesterol synthesis is associated with hepatic lipid content and dependent on fructose/glucose intake in healthy humansEzetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic ratsAnacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease.Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis.Physiological role of hepatic NPC1L1 in human cholesterol and lipoprotein metabolism: new perspectives and open questions.Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammationThe Interpretation of Cholesterol Balance Derived Synthesis Data and Surrogate Noncholesterol Plasma Markers for Cholesterol Synthesis under Lipid Lowering TherapiesHepatic triglyceride content in individuals with reduced intestinal cholesterol absorption due to variants in Nieman Pick C1-like 1.Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolismDyslipidemia in patients with nonalcoholic fatty liver disease.Phytosterols protect against diet-induced hypertriglyceridemia in Syrian golden hamsters.Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.Therapies targeting exogenous cholesterol uptake: new insights and controversies.Current therapeutic strategies in non-alcoholic fatty liver disease.Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.Intestinal and hepatic niemann-pick c1-like 1.Demystifying the management of hypertriglyceridaemia.Cardiometabolic impact of non-statin lipid lowering therapies.Critical review of non-statin treatments for dyslipoproteinemia.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Ezetimibe Increases Endogenous Cholesterol Excretion in Humans.Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.Role of ezetimibe in non-alcoholic fatty liver disease.Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis.Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
P2860
Q26738307-39187ADC-56D4-4BAA-AB64-EB3E055B0D10Q26782231-6279FB71-09CA-4BB1-9133-8940697B75F8Q30465608-EC05366A-30F4-4CEC-905B-4AB34E3CE7F6Q33802278-56933563-ED1E-49E2-8027-3C592C3075C0Q33863703-9AE1BBFF-7A7D-4310-B194-75F911847199Q34168532-21DE87A9-921D-44EF-BB2D-BA60EFAAAC92Q34187966-B7732851-1F82-4BA5-814F-F7374CF23694Q34247195-3F41AE53-7FD0-4279-92D6-38C1BE391999Q35014238-FD20A865-EDCA-4F0D-895A-A7D0E606D5B6Q35045813-7C76B764-FF2C-4B6B-878C-5705D7EA7A6DQ35607325-6AD0BFE6-A32A-494E-8EA4-8CF215201413Q35819533-9FD700CB-1D90-4AAA-8DFF-76AA6CBF5568Q35836143-F38C45BF-214C-4421-8B69-E75913BCF737Q36237764-3EC6D36E-234A-4DED-88F8-439E869173A2Q36296929-D3A53C87-2786-4263-BE5C-9FC428E45337Q36302700-A170C8F6-3246-4A0C-B388-75151AF180F7Q36302750-AD3B1A4D-CDFE-49A1-B20D-B7531DEE9733Q36315691-ED34427C-6A26-4475-97E6-B6F53002E3E7Q36382844-AD01B735-16BB-4907-B664-20364AEF4E44Q36720511-996A8F85-EB13-4000-903A-6A72D7BB248CQ36845703-B06750CD-9821-44D3-8205-54B1B1F34211Q37497908-81F8E04A-459C-48FF-A158-0F0CBC6DA737Q37604513-7EAE713D-2A8F-4629-9A1C-DD68E586BDFFQ37662878-FFBB8269-EB40-452C-A968-54D98E846000Q37772510-1F10F468-FEF6-4DFC-B7F9-513707E47999Q37824292-22904FAF-2E41-487A-A5CD-1ECDC082866EQ37859419-13F5E83F-39F7-412D-B26F-74215E7E948BQ37978785-93EA4715-49D9-4D2A-B29F-E84E008CDFFFQ38076370-34397E74-A007-4D74-84E5-57E55203BF83Q38132749-B4A7E4A5-5342-48E2-B9B3-4A3D95C1E296Q38141575-03A28646-30BA-45BC-BECB-B0A1F34C3ED6Q38176275-557AE080-138B-4E68-A7AE-2236B5E687A4Q38186099-F8CBFA6C-50DA-40A0-B768-5C0FE79F71C7Q38261236-AA639F9F-732E-4174-905F-4A9844CDBEC6Q38379633-A1466BDB-C9A3-4B93-99FE-E19E5BEDBF9BQ38397177-D740C28E-D79D-4C5F-A927-C0FEA39BFBECQ38941024-8FF8B9CF-1C11-45C0-832E-34C305AB6661Q38974667-D8ABD53E-410C-4ED6-A90F-FE79AB4169E7Q38976172-20EBF5AD-E934-4988-89D6-1D5154818A76Q39170225-7E17FCBA-CF21-4603-A628-34543E4A12BD
P2860
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of ezetimibe on hepatic ...... subjects on a weight loss diet
@ast
Effect of ezetimibe on hepatic ...... subjects on a weight loss diet
@en
type
label
Effect of ezetimibe on hepatic ...... subjects on a weight loss diet
@ast
Effect of ezetimibe on hepatic ...... subjects on a weight loss diet
@en
prefLabel
Effect of ezetimibe on hepatic ...... subjects on a weight loss diet
@ast
Effect of ezetimibe on hepatic ...... subjects on a weight loss diet
@en
P2860
P50
P356
P1433
P1476
Effect of ezetimibe on hepatic ...... subjects on a weight loss diet
@en
P2093
Seng Khee Gan
P2860
P304
P356
10.2337/DC09-1765
P407
P577
2010-02-25T00:00:00Z